When evaluating the safety of SGLT-2 inhibitors in patients with stage G4 DKD, it is crucial to consider both their positive impact on the heart and kidneys, as well as any potential negative side effects they may cause. The gene discussed is SLC5A2; the disease is diabetic kidney disease.